Why Regeneron's Praluent Is Likely To Be Removed From The U.S. Market This Year

By: via Benzinga
Chardan Capital’s Gbola Amusa maintained a Sell rating for Regeneron Pharmaceuticals Inc (NASDAQ: REGN), with a price target of ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.